Prophylactic pegfilgrastim support with adjuvant docetaxel, doxorubicin and cyclophosphamide (TAC) in node-positive breast cancer patients

被引：0
|
作者：
Rifa, Juli [1 ]
Del Alba, A. Gonzalez [1 ]
Perello, A. [1 ]
Alarcon, J. [1 ]
Avella, A. [1 ]
机构：
[1] Hosp Son Dureta, Palma De Mallorca, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer
    Gradishar, WJ
    Wedam, SB
    Jahanzeb, M
    Erban, J
    Limentani, SA
    Tsai, KT
    Olsen, SR
    Swain, SM
    ANNALS OF ONCOLOGY, 2005, 16 (08) : 1297 - 1304
  • [42] Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: Results of a feasibility study
    Cardoso, F
    Ferreira, AF
    Crown, J
    Dolci, S
    Paesmans, M
    Riva, A
    Di Leo, A
    Piccart, MJ
    ANTICANCER RESEARCH, 2001, 21 (1B) : 789 - 795
  • [43] Erratum to: Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer
    A. Messori
    P. Becagli
    S. Trippoli
    E. Tendi
    European Journal of Clinical Pharmacology, 1997, 51 : 427 - 427
  • [44] Epirubicin for adjuvant therapy in node-positive breast cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2000, 42 (1071): : 12 - 13
  • [45] Prevention of infection after TAC chemotherapy for node-positive breast cancer as an adjuvant therapy with or without ciprofloxacin
    Suh, Y.
    Chun, C.
    Oh, S.
    Song, B.
    Jung, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] PREVENTION OF INFECTION AFTER TAC CHEMOTHERAPY FOR NODE-POSITIVE BREAST CANCER AS AN ADJUVANT THERAPY WITH OR WITHOUT CIPROFLOXACIN
    Suh, Y.
    Chun, C.
    Oh, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 81 - 81
  • [47] Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial
    Mackey, J. R.
    Pienkowski, T.
    Crown, J.
    Sadeghi, S.
    Martin, M.
    Chan, A.
    Saleh, M.
    Sehdev, S.
    Provencher, L.
    Semiglazov, V.
    Press, M. F.
    Sauter, G.
    Lindsay, M.
    Houe, V.
    Buyse, M.
    Drevot, P.
    Hitier, S.
    Bensfia, S.
    Eiermann, W.
    ANNALS OF ONCOLOGY, 2016, 27 (06) : 1041 - 1047
  • [48] Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28
    Mamounas, EP
    Bryant, J
    Leinbersky, B
    Fehrenbacher, L
    Sedlacek, SM
    Fisher, B
    Wickerham, DL
    Yothers, G
    Soran, A
    Wolmark, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3686 - 3696
  • [49] Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC):: impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
    Martin, M.
    Lluch, A.
    Segui, M. A.
    Ruiz, A.
    Ramos, M.
    Adrover, E.
    Roriguez-Lescure, A.
    Grosse, R.
    Calvo, L.
    Fernandez-Chacon, C.
    Roset, M.
    Anton, A.
    Isla, D.
    Martinez del Prado, P.
    Iglesias, L.
    Zaluski, J.
    Arcusa, A.
    Loez-Vega, J. M.
    Munoz, M.
    Mel, J. R.
    ANNALS OF ONCOLOGY, 2006, 17 (08) : 1205 - 1212
  • [50] Mechanistic evidence associated with the benefit of plinabulin significantly reducing Bone pain in breast cancer patients (pts) treated with TAC (docetaxel, doxorubicin, cyclophosphamide) and pegfilgrastim (Peg)
    Blayney, Douglas W.
    Ogenstad, Stephan
    Chang, Mengru
    Lelorier, Yvette
    Huang, Lan
    Mohanlal, Ramon
    CANCER RESEARCH, 2022, 82 (04)
12345